08.21.2024
Fast Track Initiative (hereinafter referred to as ‘FTI’) has made an additional investment in AIRNA, a US-based biotech startup pioneering RNA editing therapeutics. This investment is part of AIRNA’s Series A extension round, which raised $60 million, bringing the total Series A funding to $90 million.
AIRNA is developing innovative RNA editing therapies designed to target diseases that cannot be treated with traditional approaches. Their therapies offer the potential for repeat dosing and simplified manufacturing, advancing a new class of medicines that address previously untreatable conditions. AIRNA’s flagship technology, the RESTORE+™ RNA editing platform, is currently focused on developing treatments for Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disorder. With this latest round of funding, AIRNA is positioned to accelerate the clinical development of its AATD program and other RNA editing therapies.
FTI is thrilled to strengthen its partnership with AIRNA as they work to deliver groundbreaking RNA editing therapies to patients in need. AIRNA’s cutting-edge platform holds the potential to transform the treatment of genetic diseases, and FTI is proud to be a part of their continued growth and advancement toward clinical milestones.
About AIRNA
AIRNA is pioneering the discovery and development of RNA editing therapeutics to deliver on the promise of genetically defined medicines for patients with rare and common diseases. RNA editing is poised to lead the next generation of RNA therapeutics by targeting diseases not accessible through other approaches with a medicine that can be conveniently re-dosed and manufactured. AIRNA’s founders, Thorsten Stafforst (University of Tübingen) and Jin Billy Li (Stanford University), were the first to elucidate a therapeutic approach for precise editing of RNA. AIRNA has advanced this groundbreaking research to establish the RESTORE+™ RNA editing platform to restore patients’ health. AIRNA has headquarters in Cambridge, MA, with research operations in Tübingen, Germany. Further information can be found at www.airna.com.
About Fast Track Initiative:
Established in 2004, Fast Track Initiative, Inc. (FTI) is a life science venture capital firm focusing its investments on early-stage startups with a strong focus on biotech and therapeutics. FTI has a strict mission to make a ground-breaking impact on the quality of our life and human wellness through investments across a broad range of areas in the life science community including therapeutics, diagnostics, digital health, healthcare services, and more. The company provides valuable, hands-on support to its 40+ portfolio companies through business and R&D strategy, partnering, investor syndication, and more, including access to its network of professionals in Japan.
Visit https://us.fasttrackinitiative.com for more details, or follow us on LinkedIn: https://www.linkedin.com/company/fast-track-initiative/
Media Contact:
For press inquiries or investor inquiries, please email: message.us@fasttrackinitiative.com
